Tekla Capital Management’s Theravance Biopharma TBPH Stock Holding History

Tekla Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-656,296	Closed	-$7.25M	–	180
2021 Q4	$7.25M	Hold	656,296	–	–	0.23%	83
2021 Q3	$4.86M	Hold	656,296	–	–	0.16%	110
2021 Q2	$9.53M	Buy	656,296 +200,000	+44%	+$3.76M	0.31%	84
2021 Q1	$9.31M	Hold	456,296	–	–	0.32%	80
2020 Q4	$8.11M	Buy	456,296 +157,826	+53%	+$2.83M	0.28%	96
2020 Q3	$4.41M	Buy	298,470 +69,634	+30%	+$1.3M	0.17%	111
2020 Q2	$4.8M	Hold	228,836	–	–	0.18%	104
2020 Q1	$5.29M	Buy	228,836 +111,111	+94%	+$2.78M	0.24%	82
2019 Q4	$3.05M	Buy	117,725 +71,624	+155%	+$1.39M	0.12%	137
2019 Q3	$898K	Buy	+46,101	New	+$931K	0.04%	163
2018 Q4	–	Sell	-8,083	Closed	-$264K	–	210
2018 Q3	$264K	Hold	8,083	–	–	0.01%	205
2018 Q2	$183K	Hold	8,083	–	–	0.01%	177
2018 Q1	$196K	Buy	+8,083	New	+$222K	0.01%	186

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Tekla Capital Management's TBPH Position: Q1 2022 in Review

Tekla Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2022, closing a stake of 656,296 shares — an estimated $7.25M sold.

Tekla Capital Management first reported a position in TBPH in Q1 2018 and held it in 13 quarters. The position peaked at $9.53M in Q2 2021. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2022.

Tekla Capital Management reported no remaining Theravance Biopharma position as of Q1 2022 after selling out during the quarter.
Tekla Capital Management sold 656,296 Theravance Biopharma shares in Q1 2022, an estimated $7.25M.
Tekla Capital Management first reported a position in Theravance Biopharma in Q1 2018 and held it in 13 quarters.
Tekla Capital Management's Theravance Biopharma position peaked at $9.53M in Q2 2021.
121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2022.

Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.